Comparison between novel unilateral uniportal endoscopic lumbar interbody fusion and conventional transforaminal lumbar interbody fusion for lumbar degenerative disease with bilateral symptoms: A 1-year follow-up retrospective cohort study

新型单侧单孔内镜下腰椎椎间融合术与传统经椎间孔腰椎椎间融合术治疗双侧症状腰椎退行性疾病的比较:一项为期1年的回顾性队列研究

阅读:1

Abstract

BACKGROUND CONTEXT: Full endoscopic lumbar interbody fusion (FELIF) is a minimally invasive alternative to open transforaminal lumbar interbody fusion (open-TLIF) for lumbar degenerative disease (LDD). This study aimed to compare 1-year outcomes of a modified trans-Kambin FELIF, termed Kambin Torpedo FELIF (KT-FELIF), with those of conventional open-TLIF. METHODS: In this retrospective cohort study, 76 patients with single-level LDD and bilateral symptoms underwent KT-FELIF (n=30) or open-TLIF (n=46) between January 2020 and January 2024. Patients with prior spinal surgery, multilevel disease, or incomplete follow-up imaging were excluded. Perioperative data, pain scores [visual analog scale (VAS)], radiologic outcomes, and complications were compared at ≥12-month follow-up. RESULTS: KT-FELIF showed significantly lower blood loss (72.00±62.00 mL vs. 173.91±134.37 mL, p<.01) and faster ambulation (1.37±0.49 vs. 2.30±0.81 days, p<.01) than conventional open-TLIF. Both groups showed significant VAS score improvement, but KT-FELIF offered better early pain relief (2 weeks and 6 months, p<.01). Fusion rates were similar (97% vs. 91%, p=.654), though open-TLIF had larger fusion mass (p=.005). KT-FELIF led to greater lumbar lordosis (p=.038) and spinal canal area gains (p=.002), while open-TLIF improved foraminal height more. Complication rates were comparable. CONCLUSIONS: KT-FELIF is a safe, effective, and less invasive alternative to open-TLIF for LDD with bilateral symptoms, offering benefits in blood loss, recovery time, and early pain relief, with comparable fusion and radiologic outcomes. Further long-term multicenter studies are warranted.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。